Egfr - epidermal growth factor receptor Gene

中文名称：表皮生长因子受体

种属: Mus musculus

同用名: Wa5; wa2; Erbb; Errp; wa-2; Errb1; 9030024J15Rik

基因 ID: 13649 | 基因类型: protein coding

关于 Egfr

Chromosome 11: 16,702,203-16,868,158 forward strand.GRCm39:CM001004.3

This gene has 5 transcripts (splice variants), 283 orthologues, 53 paralogues and is associated with 180 phenotypes. Broad expression in liver adult (RPKM 26.7), liver E18 (RPKM 8.7) and 15 other tissues.

功能概要

该基因编码的蛋白可启动表皮生长因子结合活性和表皮生长因子激活受体活性。参与细胞对氨基酸刺激的反应和成纤维细胞增殖的正调节。作用于多个过程的上游或内部，包括动物器官发育；表皮生长因子受体信号通路；和蛋白质自身磷酸化。位于几种细胞成分中，包括基底外侧质膜；内吞囊泡；和细胞质的核周区。以多种结构表达，包括消化系统；脑;外皮系统；肢;和呼吸系统。用于研究冠状病毒感染性疾病和主动脉瓣疾病。该基因的人类直系同源物与多种疾病有关，包括结直肠癌；肺非小细胞癌（多发性）；胰腺癌;前列腺癌;和肺结核。与人类 EGFR（表皮生长因子受体）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables epidermal growth factor binding activity and epidermal growth factor-activated receptor activity. Involved in cellular response to amino acid stimulus and positive regulation of fibroblast proliferation. Acts upstream of or within several processes, including animal organ development; epidermal growth factor receptor signaling pathway; and protein autophosphorylation. Located in several cellular components, including basolateral plasma membrane; endocytic vesicle; and perinuclear region of cytoplasm. Is expressed in several structures, including alimentary system; brain; integumental system; limb; and respiratory system. Used to study Coronavirus infectious disease and aortic valve disease. Human ortholog(s) of this gene implicated in several diseases, including colorectal cancer; lung non-small cell carcinoma (multiple); pancreatic cancer; prostate cancer; and pulmonary tuberculosis. Orthologous to human EGFR (epidermal growth factor receptor). [provided by Alliance of Genome Resources, Apr 2022]

Egfr 基因产物(2)

mRNA	Protein	Name
NM_207655.2	NP_997538.1	epidermal growth factor receptor isoform 1 precursor
NM_007912.4	NP_031938.1	epidermal growth factor receptor isoform 2 precursor

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables epidermal growth factor binding	IDA IDA: 通过直接分析推断	7678348	MGI
enables epidermal growth factor receptor activity	IDA IDA: 通过直接分析推断	6248866	MGI
enables epidermal growth factor receptor activity	IGI IGI: 通过遗传相互作用推断	16357442	MGI
enables epidermal growth factor receptor activity	IMP IMP: 通过突变表型推断	18701712	MGI
enables kinase activity	IDA IDA: 通过直接分析推断	12808090	MGI
enables protein binding	IPI IPI: 通过物理相互作用推断	11274221	MGI
enables protein tyrosine kinase activity	IDA IDA: 通过直接分析推断	15383614	MGI
enables protein tyrosine kinase activity	IMP IMP: 通过突变表型推断	11823423	MGI
enables transmembrane receptor protein tyrosine kinase activity	IDA IDA: 通过直接分析推断	7752576	MGI
enables transmembrane receptor protein tyrosine kinase activity	IGI IGI: 通过遗传相互作用推断	28783046	MGI
enables transmembrane receptor protein tyrosine kinase activity	IMP IMP: 通过突变表型推断	12399441	MGI

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in ERBB2-EGFR signaling pathway	IDA IDA: 通过直接分析推断	8702723	MGI
involved in ERBB2-EGFR signaling pathway	IMP IMP: 通过突变表型推断	18701712	MGI
acts upstream of or within cell morphogenesis	IGI IGI: 通过遗传相互作用推断	17686994	MGI
acts upstream of cell population proliferation	IGI IGI: 通过遗传相互作用推断	18656477	MGI
involved in cellular response to amino acid stimulus	IDA IDA: 通过直接分析推断	22711986	MGI
acts upstream of or within cellular response to growth factor stimulus	IDA IDA: 通过直接分析推断	8702723	MGI
acts upstream of or within cerebral cortex cell migration	IMP IMP: 通过突变表型推断	7618084	MGI
acts upstream of or within digestive tract morphogenesis	IMP IMP: 通过突变表型推断	7618084	MGI
acts upstream of or within embryonic placenta development	IMP IMP: 通过突变表型推断	7618084	MGI
acts upstream of or within epidermal growth factor receptor signaling pathway	IDA IDA: 通过直接分析推断	14712229	MGI
involved in epidermal growth factor receptor signaling pathway	IDA IDA: 通过直接分析推断	6248866	MGI
acts upstream of or within epidermal growth factor receptor signaling pathway	IGI IGI: 通过遗传相互作用推断	7641815	MGI
involved in epidermal growth factor receptor signaling pathway	IGI IGI: 通过遗传相互作用推断	28783046	MGI
acts upstream of or within epidermal growth factor receptor signaling pathway	IMP IMP: 通过突变表型推断	17686994	MGI
involved in epidermal growth factor receptor signaling pathway	IMP IMP: 通过突变表型推断	12399441	MGI
acts upstream of or within epidermis development	IMP IMP: 通过突变表型推断	7618084	MGI
acts upstream of epithelial cell proliferation	IMP IMP: 通过突变表型推断	7618084	MGI
acts upstream of or within eyelid development in camera-type eye	IGI IGI: 通过遗传相互作用推断	9030684	MGI
acts upstream of or within hair follicle development	IGI IGI: 通过遗传相互作用推断	9030684	MGI
acts upstream of or within hair follicle development	IMP IMP: 通过突变表型推断	7618084	MGI
acts upstream of or within morphogenesis of an epithelial fold	IMP IMP: 通过突变表型推断	7618084	MGI
involved in negative regulation of epidermal growth factor receptor signaling pathway	IDA IDA: 通过直接分析推断	23457600	MGI
involved in negative regulation of epidermal growth factor receptor signaling pathway	IMP IMP: 通过突变表型推断	11823423	MGI
acts upstream of or within positive regulation of cell population proliferation	IDA IDA: 通过直接分析推断	14712229	MGI
acts upstream of or within positive regulation of cell population proliferation	IGI IGI: 通过遗传相互作用推断	7641815	MGI
acts upstream of or within positive regulation of epithelial cell proliferation	IMP IMP: 通过突变表型推断	7618084	MGI
involved in positive regulation of fibroblast proliferation	IMP IMP: 通过突变表型推断	20208556	MGI
acts upstream of or within protein autophosphorylation	IDA IDA: 通过直接分析推断	15314156	MGI
acts upstream of or within regulation of cell population proliferation	IGI IGI: 通过遗传相互作用推断	11818567	MGI
acts upstream of or within regulation of peptidyl-tyrosine phosphorylation	IMP IMP: 通过突变表型推断	11940581	MGI
acts upstream of or within salivary gland morphogenesis	IMP IMP: 通过突变表型推断	10521784	MGI
acts upstream of or within signal transduction	IDA IDA: 通过直接分析推断	11940581	MGI

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in basolateral plasma membrane	IDA IDA: 通过直接分析推断	7723235	MGI
located in cell surface	IDA IDA: 通过直接分析推断	23918928	MGI
located in endocytic vesicle	IDA IDA: 通过直接分析推断	10534613	MGI
located in intracellular anatomical structure	IDA IDA: 通过直接分析推断	10534613	MGI
located in nucleus	IDA IDA: 通过直接分析推断	20208556	MGI
located in perinuclear region of cytoplasm	IDA IDA: 通过直接分析推断	20208556	MGI
is active in plasma membrane	IDA IDA: 通过直接分析推断	6248866	MGI
located in plasma membrane	IDA IDA: 通过直接分析推断	7641815	MGI
is active in plasma membrane	IGI IGI: 通过遗传相互作用推断	28783046	MGI

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Egfr 蛋白结构

Recep_L_domain

Furin-like

Recep_L_domain

GF_recep_IV

TM_ErbB1

PTKc_EGFR

0
200
400
600
800
1000
1210 a.a.

蛋白主名

其他名称

epidermal growth factor receptor

avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

waved 2

重组 Egfr 蛋白

目录号	产品名	蛋白编号	纯度
HY-P72988	EGFR Protein, Mouse (HEK293, Fc)	Q01279 (L25-S647)	≥95%
HY-P72989	EGFR Protein, Mouse (HEK293, His)	Q01279 (L25-S647)	≥95%

相关产品

Approval

生物活性分子 (43)

目录号	产品名	作用方式	纯度	是否罕见病
HY-15772	Osimertinib	Inhibitor	99.96%	是
HY-50895	Gefitinib	Inhibitor	99.94%	是
HY-50896	Erlotinib	Inhibitor	99.99%	是
HY-138298A	Trastuzumab deruxtecan	Inhibitor	99.68%	否
HY-10261	Afatinib	Inhibitor	99.92%	是
HY-50898	Lapatinib	Inhibitor	99.83%	是
HY-138298	Trastuzumab deruxtecan (solution)	Inhibitor	99.64%	否
HY-P9921	Trastuzumab emtansine	Inhibitor	99.74%	否
HY-16069	Tucatinib	Inhibitor	99.82%	是
HY-32721	Neratinib	Inhibitor	99.94%	是
HY-P9985	Disitamab vedotin	Inhibitor	≥99.0%	否
HY-13272	Dacomitinib	Inhibitor	99.74%	是
HY-15772A	Osimertinib mesylate	Inhibitor	99.97%	是
HY-12008	Erlotinib Hydrochloride	Inhibitor	99.93%	是
HY-109061	Lazertinib	Inhibitor	99.07%	否
HY-112823	Almonertinib	Inhibitor	99.98%	否
HY-112870A	Firmonertinib mesylate	Inhibitor	99.97%	否
HY-104065	Pyrotinib	Inhibitor	99.89%	否
HY-135815	Mobocertinib	Inhibitor	99.60%	是
HY-15164A	Icotinib	Inhibitor	99.99%	是
HY-10261A	Afatinib dimaleate	Inhibitor	99.88%	是
HY-50895A	Gefitinib hydrochloride	Inhibitor	99.85%	是
HY-N0281	Daphnetin	Inhibitor	99.86%	否
HY-19730	Olmutinib	Inhibitor	99.88%	否
HY-79077	Osimertinib dimesylate	Inhibitor	99.96%	是
HY-P9921A	Trastuzumab emtansine (solution)		99.01%	否
HY-50898A	Lapatinib ditosylate	Inhibitor	99.98%	是
HY-104065B	Pyrotinib dimaleate	Inhibitor	98.56%	否
HY-15164	Icotinib Hydrochloride	Inhibitor	99.81%	是
HY-50898B	Lapatinib ditosylate monohydrate	Inhibitor	99.93%	是
HY-112823A	Almonertinib mesylate	Inhibitor	99.07%	否
HY-112823B	Almonertinib hydrochloride	Inhibitor	99.77%	否
HY-32721B	Neratinib maleate	Inhibitor	99.83%	是
HY-135815A	Mobocertinib succinate	Inhibitor	99.83%	是
HY-118263	Dacomitinib hydrate	Inhibitor	99.03%	否
HY-112870	Firmonertinib	Inhibitor	99.89%	否
HY-50895R	Gefitinib (Standard)	Inhibitor	/	否
HY-10261D	Afatinib oxalate	Inhibitor	/	否
HY-135815B	Mobocertinib mesylate	Inhibitor	/	否
HY-50895B	Gefitinib dihydrochloride	Inhibitor	/	否
HY-50898C	Lapatinib tosylate	Inhibitor	/	否
HY-101820A	Simotinib hydrochloride	Inhibitor	/	否
HY-12008A	Erlotinib mesylate	Inhibitor	/	否

抗体抑制剂 (9)

目录号	产品名	作用方式	纯度	是否罕见病
HY-P9907	Trastuzumab	Inhibitor	99.80%	否
HY-P9905	Cetuximab	Inhibitor	99.70%	否
HY-P9977	Amivantamab	Inhibitor	99.90%	否
HY-P9912	Pertuzumab	Inhibitor	99.80%	否
HY-P99041	Panitumumab	Inhibitor	98.80%	否
HY-P99380	Zanidatamab	Inhibitor	96.38%	否
HY-P9968	Nimotuzumab	Inhibitor	96.80%	否
HY-P99030	Margetuximab	Inhibitor	98.90%	否
HY-P9964	Necitumumab	Inhibitor	95.00%	否

Clinical Phase

生物活性分子 (60)

目录号	产品名	作用方式	纯度	Phase
HY-14596	Genistein	Inhibitor	99.86%	Phase 4
HY-50895G	Gefitinib (GMP)	Inhibitor	/	Phase 4
HY-132842	Sunvozertinib	Inhibitor	99.92%	Phase 3
HY-18750	Zorifertinib	Inhibitor	99.76%	Phase 3
HY-15729	Rociletinib	Inhibitor	99.79%	Phase 3
HY-13314	Tesevatinib	Inhibitor	99.21%	Phase 3
HY-19816	Avitinib	Inhibitor	99.90%	Phase 3
HY-10530	Varlitinib	Inhibitor	98.03%	Phase 3
HY-19816A	Avitinib maleate	Inhibitor	99.86%	Phase 3
HY-16069A	Tucatinib hemiethanolate	Inhibitor	99.97%	Phase 3
HY-19803	Naquotinib mesylate	Inhibitor	98.05%	Phase 3
HY-138751	limertinib	Inhibitor	99.12%	Phase 3
HY-19729	Naquotinib	Inhibitor	98.71%	Phase 3
HY-132259	Depatuxizumab mafodotin		99.73%	Phase 3
HY-15729A	Rociletinib hydrobromide	Inhibitor	98.04%	Phase 3
HY-118998	TX2-121-1	Inhibitor	/	Phase 3
HY-10530A	Varlitinib tosylate	Inhibitor	/	Phase 3
HY-106204	Nelipepimut-S		/	Phase 3
HY-13050	Sapitinib	Inhibitor	99.93%	Phase 2
HY-144680	BLU-945	Inhibitor	99.90%	Phase 2
HY-18957	Lifirafenib	Inhibitor	98.73%	Phase 2
HY-10367	Canertinib	Inhibitor	99.82%	Phase 2
HY-32718	Pelitinib	Inhibitor	98.80%	Phase 2
HY-10333	BMS-690514	Inhibitor	99.07%	Phase 2
HY-12872	Nazartinib	Inhibitor	99.03%	Phase 2
HY-112299	Zipalertinib	Inhibitor	99.81%	Phase 2
HY-10045	AEE788	Inhibitor	99.13%	Phase 2
HY-12972	Mavelertinib	Inhibitor	99.34%	Phase 2
HY-19985	PF-06459988	Inhibitor	98.87%	Phase 2
HY-136789	Tuxobertinib	Inhibitor	99.90%	Phase 2
HY-10367A	Canertinib dihydrochloride	Inhibitor	99.68%	Phase 2
HY-107367A	Epertinib hydrochloride	Inhibitor	98.25%	Phase 2
HY-157229	STX-721	Inhibitor	98.25%	Phase 2
HY-17632	Tarloxotinib bromide	Inhibitor	99.26%	Phase 2
HY-19909	NRC-2694	Antagonist	99.45%	Phase 2
HY-107367	Epertinib	Inhibitor	≥98.0%	Phase 2
HY-12872A	Nazartinib mesylate	Inhibitor	/	Phase 2
HY-10223	CUDC-101	Inhibitor	99.05%	Phase 1
HY-13501	Mubritinib	Inhibitor	99.91%	Phase 1
HY-14346	PD153035	Inhibitor	98.83%	Phase 1
HY-15196	TAK-285	Inhibitor	99.70%	Phase 1
HY-10322	Falnidamol	Inhibitor	99.41%	Phase 1
HY-B0794B	AZ7550 Mesylate	Inhibitor	99.24%	Phase 1
HY-101820	Simotinib	Inhibitor	99.39%	Phase 1
HY-103443	HKI-357	Inhibitor	99.65%	Phase 1
HY-12010	BMS-599626 Hydrochloride	Inhibitor	99.68%	Phase 1
HY-116437	Selatinib	Inhibitor	99.83%	Phase 1
HY-10346A	AV-412 free base	Inhibitor	98.33%	Phase 1
HY-104066	Theliatinib	Inhibitor	99.77%	Phase 1
HY-111553	TAS0728	Inhibitor	99.15%	Phase 1
HY-143319	SPH5030	Inhibitor	99.40%	Phase 1
HY-139300A	Epitinib succinate	Inhibitor	99.01%	Phase 1
HY-10346	AV-412	Inhibitor	99.17%	Phase 1
HY-128778	DBPR112	Inhibitor	98.37%	Phase 1
HY-B0794A	AZ7550 hydrochloride	Inhibitor	98.66%	Phase 1
HY-15732	BGB-102	Inhibitor	99.52%	Phase 1
HY-104066A	Theliatinib tartrate		/	Phase 1
HY-139300	Epitinib	Inhibitor	/	Phase 1
HY-10251	BMS-599626	Inhibitor	/	Phase 1
HY-18957B	Lifirafenib maleate	Inhibitor	/	Phase 1

抗体抑制剂 (31)

目录号	产品名	作用方式	纯度	Phase
HY-P9907A	Trastuzumab (anti-HER2)	Inhibitor	99.72%	Phase 4
HY-P99854	Disitamab	Inhibitor	≥95.0%	Phase 4
HY-P99041A	Panitumumab (anti-EGFR)	Inhibitor	98.00%	Phase 4
HY-P99969	Inetetamab	Inhibitor	96.54%	Phase 4
HY-P99275	Patritumab	Inhibitor	98.95%	Phase 3
HY-P99849	Depatuxizumab	Inhibitor	99.58%	Phase 3
HY-P99155	Zalutumumab		98.26%	Phase 3
HY-P99676	Izalontamab	Inhibitor	99.03%	Phase 3
HY-P99455	Bafisontamab	Inhibitor	96.00%	Phase 3
HY-P99437	Anbenitamab	Inhibitor	99.22%	Phase 3
HY-P99831	Coprelotamab		/	Phase 3
HY-P99630	Gancotamab	Inhibitor	/	Phase 3
HY-P99268	Seribantumab	Inhibitor	≥95.0%	Phase 2
HY-P99507	Zenocutuzumab	Inhibitor	99.20%	Phase 2
HY-P99406	Petosemtamab	Degrader	96.95%	Phase 2
HY-P9969	Matuzumab		98.12%	Phase 2
HY-P99936	Elgemtumab	Inhibitor	99.00%	Phase 2
HY-P990049	Becotatug	Inhibitor	98.44%	Phase 2
HY-P99618	Fidasimtamab	Inhibitor	95.00%	Phase 2
HY-P99216	Ponezumab	Inhibitor	99.39%	Phase 2
HY-P99306	Modotuximab	Inhibitor	99.08%	Phase 2
HY-P99866	Duligotuzumab		97.93%	Phase 2
HY-P99715	Losatuxizumab	Inhibitor	99.44%	Phase 2
HY-P99296	Intetumumab	Inhibitor	99.24%	Phase 2
HY-P99605	Cinrebafusp alfa	Inhibitor	98.53%	Phase 2
HY-P99295	Imgatuzumab	Inhibitor	99.41%	Phase 2
HY-P99628	Futuximab	Inhibitor	/	Phase 2
HY-P99672	Istiratumab	Inhibitor	/	Phase 2
HY-P99896	Runimotamab		99.00%	Phase 1
HY-P99304	Lumretuzumab	Inhibitor	≥99.0%	Phase 1
HY-P99461	Barecetamab	Inhibitor	97.96%	Phase 1

Pre-clinical Phase

生物活性分子 (556)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-12000	AG490	Inhibitor	99.92%	否
HY-13524	AG-1478	Inhibitor	99.22%	否
HY-101084	NSC 228155	Activator	≥98.0%	否
HY-N0280	Corosolic acid		99.23%	否
HY-N2409	Delphinidin chloride	Inhibitor	≥98.0%	否
HY-13595	Chrysophanol	Inhibitor	99.77%	否
HY-100848	TX1-85-1	Inhibitor	98.04%	否
HY-16558	Butein	Inhibitor	99.95%	否
HY-12461	WS6	Activator	99.94%	否
HY-100213	EAI045	Inhibitor	99.08%	否
HY-123921	Gefitinib-based PROTAC 3	Inhibitor	99.98%	否
HY-B0793	AZ-5104	Inhibitor	99.69%	否
HY-P10408	Candidalysin	Activator	99.38%	否
HY-14674	CP-724714	Inhibitor	98.37%	否
HY-15730	Poziotinib	Inhibitor	99.96%	否
HY-15644	Tyrphostin 23	Inhibitor	99.43%	否
HY-18609	PD158780	Inhibitor	99.56%	否
HY-13896	PD168393	Inhibitor	98.58%	否
HY-129550	BI-4020	Inhibitor	99.28%	否
HY-15844	AG-825	Inhibitor	98.02%	否
HY-12026	WZ4002	Inhibitor	99.76%	否
HY-147183B	JBJ-09-063 hydrochloride	Inhibitor	99.37%	否
HY-109189	Rezivertinib	Inhibitor	99.43%	否
HY-108052	Delphinidin 3-glucoside chloride	Inhibitor	99.89%	否
HY-141676	HyT36	Degrader	≥96.0%	否
HY-13427	Allitinib tosylate	Inhibitor	99.83%	否
HY-N2450	Sulforaphene	Inhibitor	99.80%	否
HY-W016412	Coenzyme Q0	Inhibitor	99.88%	否
HY-153268	BDTX-1535	Inhibitor	99.03%	否
HY-14596R	Genistein (Standard)	Inhibitor	99.31%	否
HY-14596S	Genistein-d4	Inhibitor	98.81%	否
HY-12001	WZ-3146	Inhibitor	99.63%	否
HY-111138	CZC-8004	Inhibitor	99.81%	否
HY-125168	EGA	Modulator	≥99.0%	否
HY-20878	Tyrphostin AG 879	Inhibitor	99.85%	否
HY-123578	NSC689857	Inhibitor	99.65%	否
HY-N0211	Cyasterone	Inhibitor	99.58%	否
HY-162713	MTX-531	Inhibitor	99.87%	否
HY-P1845	PACAP-38 (31-38), human, mouse, rat	Inducer	99.98%	否
HY-P1845A	PACAP-38 (31-38), human, mouse, rat TFA	Inducer	98.33%	否
HY-112411	PD 174265	Inhibitor	98.72%	否
HY-78869	Mutated EGFR-IN-1	Inhibitor	99.84%	否
HY-147941A	MS9427 TFA	Degrader	99.01%	否
HY-144880	SC209	Inhibitor	99.52%	否
HY-107364	MTX-211	Inhibitor	99.81%	否
HY-137191	CH7233163	Inhibitor	99.61%	否
HY-N2510	Myristicin	Inhibitor	99.89%	否
HY-101219	VEGFR-IN-1	Inhibitor	98.42%	否
HY-100434	PD-161570	Inhibitor	99.82%	否
HY-10325	CL-387785	Inhibitor	98.05%	否
HY-13895	WHI-P154	Inhibitor	99.39%	否
HY-141640	MS154	Inhibitor	99.42%	否
HY-137433	Befotertinib	Inhibitor	99.86%	否
HY-142283AS	Dosimertinib mesylate	Inhibitor	99.44%	否
HY-103440	EGFR/ErbB-2/ErbB-4 inhibitor-3	Inhibitor	98.19%	否
HY-10261B	(E/Z)-Afatinib	Inhibitor	99.98%	否
HY-155537	YK-029A	Inhibitor	99.50%	否
HY-12029	WZ8040	Inhibitor	99.22%	否
HY-19815	Olafertinib	Inhibitor	99.51%	否
HY-134877	BAY 2476568	Inhibitor	99.88%	否
HY-135805A	(Rac)-JBJ-04-125-02	Inhibitor	/	否
HY-150024	BI-4142	Inhibitor	98.39%	否
HY-147219A	SIAIS164018 hydrochloride	Inhibitor	99.84%	否
HY-124813	PDZ1i	Inhibitor	99.29%	否
HY-107459	(E/Z)-AG490	Inhibitor	99.97%	否
HY-N1166	Tephrosin		98.02%	否
HY-150611	EGFR-IN-70	Inhibitor	99.16%	否
HY-43533	Tarlox-TKI	Inhibitor	98.84%	否
HY-15801	HG-14-10-04	Inhibitor	99.09%	否
HY-B1394	Khellin	Inhibitor	99.89%	否
HY-12013	PD153035 Hydrochloride	Inhibitor	99.48%	否
HY-150023	BI-1622	Inhibitor	98.97%	否
HY-147183A	JBJ-09-063 TFA	Inhibitor	99.64%	否
HY-153110A	Larotinib mesylate hydrate	Inhibitor	98.66%	否
HY-139920	Oritinib	Inhibitor	99.18%	否
HY-138627A	AST5902 trimesylate	Inhibitor	98.75%	否
HY-101450	PF-6274484	Inhibitor	98.76%	否
HY-115481	EphB1-IN-1	Inhibitor	99.87%	否
HY-41404	Piperonylic acid		99.91%	否
HY-120590	Ruserontinib	Inhibitor	99.82%	否
HY-103566	LY456236	Inhibitor	99.81%	否
HY-124674A	CCT365623 hydrochloride	Inhibitor	98.07%	否
HY-123952	RTC-5	Inhibitor	99.89%	否
HY-101041	(E)-AG 556	Inhibitor	99.92%	否
HY-18603	FIIN-3	Inhibitor	99.66%	否
HY-147942	MS9449		98.95%	否
HY-136430	JCN037	Inhibitor	99.76%	否
HY-101960A	Tyrphostin A51	Inhibitor	≥99.0%	否
HY-17499	EGFR-IN-12	Inhibitor	99.40%	否
HY-157581	MS39	Degrader	99.2%	否
HY-112293	GW2974		99.54%	否
HY-101042	AG-494	Inhibitor	99.31%	否
HY-P5314	OK2	Inhibitor	95.95%	否
HY-144304	PROTAC EGFR degrader 2	Inhibitor	95.61%	否
HY-N4201	β-Hydroxyisovalerylshikonin	Inhibitor	99.83%	否
HY-117155	PKI-166	Inhibitor	99.58%	否
HY-112420	EGFR/ErbB-2/ErbB-4 inhibitor-2	Inhibitor	99.45%	否
HY-12008S	Erlotinib-d6 hydrochloride	Inhibitor	98.13%	否
HY-113599	Isoprocurcumenol	Activator	95.41%	否
HY-15769	WHI-P180	Inhibitor	99.84%	否
HY-131865	SJF-1521	Degrader	99.65%	否
HY-141481	DP-C-4	Inhibitor	98.15%	否
HY-100214	EAI001	Inhibitor	99.88%	否
HY-130616	EGFR-IN-11	Inhibitor	99.30%	否
HY-155079	DZD1516		98.31%	否
HY-133780	Afatinib impurity 11	Inhibitor	99.10%	否
HY-P1828A	EGFRvIII peptide (PEPvIII) TFA		96.83%	否
HY-15336	AG 555	Inhibitor	≥98.0%	否
HY-100499	Tyrphostin AG 528	Inhibitor	≥98.0%	否
HY-155736	MAPK-IN-2	Inhibitor	98.54%	否
HY-18963	Lavendustin A	Inhibitor	98.02%	否
HY-135805B	(Rac)-JBJ-04-125-02 acetate		96.58%	否
HY-112345	PD-089828	Inhibitor	98.07%	否
HY-N2184	Furanodienone		99.90%	否
HY-153901	PROTAC EGFR degrader 8	Inhibitor	98.90%	否
HY-W018800	4(3H)-Quinazolinone	Inhibitor	99.91%	否
HY-13984	Mutant EGFR inhibitor	Inhibitor	99.51%	否
HY-N6577	Astragaloside VI		99.95%	否
HY-108016	Peruvoside	Inhibitor	99.32%	否
HY-103442	CGP52411	Inhibitor	99.82%	否
HY-108484	PP 3	Inhibitor	98.78%	否
HY-157480	EGFR/AURKB-IN-1	Inhibitor	99.43%	否
HY-10261S	Afatinib-d6	Inhibitor	≥99.0%	否
HY-13897	CNX-2006	Inhibitor	98.42%	否
HY-131864A	SJF-1528 hemihydrate	Degrader	98.90%	否
HY-15772S	Osimertinib-d6	Inhibitor	99.97%	否
HY-128862	EGFR-IN-7	Inhibitor	99.76%	否
HY-126320	EGFR-IN-8	Inhibitor	98.01%	否
HY-100962	(E)-AG 99	Inhibitor	98.36%	否
HY-111415	EGFR-IN-5	Inhibitor	98.64%	否
HY-W013857	Lavendustin C	Inhibitor	98.32%	否
HY-156284	EGFR-IN-89	Inhibitor	98.75%	否
HY-161536	PROTAC EGFR degrader 9	Inhibitor	98.35%	否
HY-138072	EMI1	Inhibitor	99.78%	否
HY-118532	Tyrphostin AG30	Inhibitor	99.70%	否
HY-101429	RG13022	Inhibitor	96.74%	否
HY-152098	HX103	Inhibitor	99.10%	否
HY-P1855	HER2/neu (654-662) GP2		98.04%	否
HY-161927	EGFR-TK-IN-4	Inhibitor	99.90%	否
HY-163094	EGFR-IN-95	Inhibitor	/	否
HY-100923	H-9 Dihydrochloride	Inhibitor	98.98%	否
HY-142512	EGFR-IN-24	Inhibitor	/	否
HY-146349	PROTAC EGFR degrader 4	Inhibitor	99.70%	否
HY-10531	ARRY-380 analog	Inhibitor	99.19%	否
HY-15772S1	Osimertinib-13C,d3		99.14%	否
HY-161537	EGFR ligand-9	Inhibitor	98.80%	否
HY-149889	EGFR-IN-78	Inhibitor	/	否
HY-131864	SJF-1528	Degrader	99.71%	否
HY-161275	BI-4732	Inhibitor	99.30%	否
HY-101426	RG14620	Inhibitor	98.09%	否
HY-147858	PROTAC EGFR degrader 7	Inhibitor	99.99%	否
HY-161126	EGFR-IN-98	Inhibitor	99.12%	否
HY-149530	EGFR-IN-86	Inhibitor	/	否
HY-162299	EGFR kinase inhibitor 3	Inhibitor	/	否
HY-153111	EGFR/HER2-IN-9	Inhibitor	98.73%	否
HY-50898S	Lapatinib-d4	Inhibitor	99.02%	否
HY-103441	JNJ28871063 hydrochloride	Inhibitor	98.36%	否
HY-W087187	DOTAGA-anhydride		/	否
HY-U00002	ZD-4190	Inhibitor	98.08%	否
HY-15375	Allitinib	Inhibitor	99.36%	否
HY-50895S	Gefitinib-d8	Inhibitor	98.42%	否
HY-163428	ZN-A-1041	Inhibitor	/	否
HY-19617A	EGFR-IN-1 hydrochloride	Inhibitor	/	否
HY-119944	JND3229	Inhibitor	99.78%	否
HY-145960	MC-Val-Cit-PAB-Amide-TLR7 agonist 4	Agonist	99.39%	否
HY-130608	Mutated EGFR-IN-3	Inhibitor	/	否
HY-147183	JBJ-09-063	Inhibitor	/	否
HY-147941	MS9427	Degrader	95.29%	否
HY-153110	Larotinib	Inhibitor	99.50%	否
HY-147219	SIAIS164018	Inhibitor	/	否
HY-132842A	(S)-Sunvozertinib	Inhibitor	99.14%	否
HY-138627	AST5902	Inhibitor	/	否
HY-19617	EGFR-IN-1	Inhibitor	/	否
HY-115716	EGFR-IN-17	Inhibitor	98.42%	否
HY-135805	JBJ-04-125-02	Inhibitor	/	否
HY-155285	YS-363	Inhibitor	99.52%	否
HY-50895S1	Gefitinib-d6	Inhibitor	≥98.0%	否
HY-155358	Os30	Inhibitor	98.34%	否
HY-158310	SOS1/EGFR-IN-1	Inhibitor	99.54%	否
HY-143337	EGFR-IN-47	Inhibitor	96.01%	否
HY-B0794	AZ7550	Inhibitor	/	否
HY-13272S2	Dacomitinib-d10 dihydrochloride	Inhibitor	≥95.0%	否
HY-150610	EGFR-IN-69	Inhibitor	99.58%	否
HY-162254	EGFR/ACK1-IN-1	Inhibitor	/	否
HY-12872B	Nazartinib S-enantiomer		98.66%	否
HY-149636	Multi-target kinase inhibitor 2	Inhibitor	99.82%	否
HY-101522	CHMFL-EGFR-202	Inhibitor	99.75%	否
HY-100064	O-Desmethyl gefitinib	Inhibitor	99.40%	否
HY-161408	GePhos1		/	否
HY-126319	SU5204	Inhibitor	99.46%	否
HY-103439	GW583340 dihydrochloride	Inhibitor	/	否
HY-157579	MS154N		99.30%	否
HY-144677	pan-HER-IN-2	Inhibitor	98.10%	否
HY-161633	PROTAC EGFR degrader 11	Degrader	99.20%	否
HY-P2673A	Lys-Arg-Thr-Leu-Arg-Arg acetate		/	否
HY-12806	AG1557	Inhibitor	99.54%	否
HY-P2503	EGFR Protein Tyrosine Kinase Substrate		99.05%	否
HY-19617B	EGFR-IN-1 TFA	Inhibitor	99.38%	否
HY-50896S	Erlotinib-d6	Inhibitor	/	否
HY-101007A	(+)-Tyrphostin B44	Inhibitor	97.01%	否
HY-155005	EGFR mutant-IN-2	Inhibitor	≥97.0%	否
HY-101006	Methyl 2,5-dihydroxycinnamate	Inhibitor	99.70%	否
HY-111452	EGFR-IN-85	Inhibitor	/	否
HY-P2673	Lys-Arg-Thr-Leu-Arg-Arg		/	否
HY-157413	YS-67	Inhibitor	99.41%	否
HY-158149	T-1-PMPA	Inhibitor	99.70%	否
HY-13450	ZM 449829	Inhibitor	99.73%	否
HY-101756	SDZ281-977		98.00%	否
HY-138751A	limertinib diTFA	Inhibitor	≥98.0%	否
HY-18750A	Zorifertinib hydrochloride	Inhibitor	/	否
HY-142283	Dosimertinib	Inhibitor	/	否
HY-19981B	Derazantinib dihydrochloride	Inhibitor	/	否
HY-135914	JBJ-02-112-05	Inhibitor	/	否
HY-128860	Mutated EGFR-IN-2	Inhibitor	/	否
HY-163354	EGFR-IN-103	Inhibitor	/	否
HY-143734	HER2-IN-6		/	否
HY-132883	EGFR/CSC-IN-1	Inhibitor	/	否
HY-131067	EMI56	Inhibitor	99.72%	否
HY-115951	EGFR/HER2-IN-2	Inhibitor	/	否
HY-147407	Imbotolimod	Inhibitor	/	否
HY-10407G	SU 5402 (GMP)	Inhibitor	/	否
HY-125841	EGFR mutant-IN-1	Inhibitor	/	否
HY-139920A	Oritinib mesylate	Inhibitor	/	否
HY-147303	Sacibertinib	Inhibitor	/	否
HY-131066	EMI48	Inhibitor	99.02%	否
HY-138746	EGFR-IN-15	Inhibitor	/	否
HY-144048	EGFR-IN-31		/	否
HY-143729	EGFR-IN-29	Inhibitor	/	否
HY-161781	HVH-2930	Inhibitor	/	否
HY-123891	NS-062	Inhibitor	/	否
HY-163657	HER2-IN-20	Inhibitor	/	否
HY-RS04209	EGFR Human Pre-designed siRNA Set A	Inhibitor	/	否
HY-146127	Grb2 SH2 domain inhibitor 1	Inhibitor	/	否
HY-162483	EGFR kinase inhibitor 6	Inhibitor	/	否
HY-13272S3	Dacomitinib-d10	Inhibitor	/	否
HY-100636A	Gefitinib N-oxide hydrochloride	Inhibitor	/	否
HY-RS04211	Egfr Rat Pre-designed siRNA Set A	Inhibitor	/	否
HY-158018	EGFR-TK-IN-2	Inhibitor	/	否
HY-156097	Anticancer agent 158	Inhibitor	/	否
HY-162482	EGFR kinase inhibitor 5	Inhibitor	/	否
HY-158829	SSOe26 sodium		/	否
HY-112405	BPIQ-I	Inhibitor	/	否
HY-153557A	HER2-IN-14	Inhibitor	/	否
HY-10261AS	Afatinib-d6 dimaleate	Inhibitor	/	否
HY-157402	Topoisomerase II/EGFR-IN-1		/	否
HY-163632	EGFR-IN-112	Inhibitor	/	否
HY-100064S1	O-Desmethyl gefitinib-d6	Inhibitor	/	否
HY-147741	DPPY	Inhibitor	/	否
HY-143246	EGFR kinase inhibitor 1	Inhibitor	/	否
HY-158828	SSO111 sodium		/	否
HY-168170	EGFR/VEGFR2-IN-2	Inhibitor	/	否
HY-158153	EGFR-IN-108	Inhibitor	/	否
HY-157399	EGFR/HER2-IN-10	Inhibitor	/	否
HY-163726	GLUT1/EGFR-IN-1	Inhibitor	/	否
HY-145823	EGFR-IN-42	Inhibitor	/	否
HY-144050	EGFR-IN-33	Inhibitor	/	否
HY-152144	EGFR-IN-75	Inhibitor	/	否
HY-146239	EGFR/HER2/TS-IN-2	Inhibitor	/	否
HY-149556	MTX-241F	Inhibitor	/	否
HY-164489	KU004	Inhibitor	/	否
HY-149824	EGFR T790M/L858R-IN-2	Inhibitor	99.66%	否
HY-164307	Pebezertinib	Inhibitor	99.56%	否
HY-149517	EGFR/BRAFV600E-IN-2	Inhibitor	/	否
HY-143323	HER2-IN-9	Inhibitor	/	否
HY-168655	EGFR/VEGFR2-IN-3	Inhibitor	/	否
HY-126850	4-Epidoxycycline		/	否
HY-103437	EGFR-IN-80	Inhibitor	/	否
HY-163402	EGFR-IN-108 chloride	Inhibitor	/	否
HY-163434	PRMT5/EGFR-IN-1	Inhibitor	/	否
HY-137028	2′-Thioadenosine	Inhibitor	/	否
HY-158154	EGFR-IN-110	Inhibitor	/	否
HY-156912	Tyrosine kinase-IN-7	Inhibitor	99.25%	否
HY-169408	EGFR-IN-137	Inhibitor	/	否
HY-155227	ALK/EGFR-IN-1	Inhibitor	/	否
HY-113549	Erbstatin	Inhibitor	/	否
HY-157994	EGFR WT/T790M-IN-2	Inhibitor	/	否
HY-163723	EGFR-IN-116	Inhibitor	/	否
HY-168073	EGFR/VEGFR2-IN-1	Inhibitor	/	否
HY-118175	RG 14921	Inhibitor	/	否
HY-150781	EGFR-IN-71	Inhibitor	/	否
HY-168514	SOS1/EGFR-IN-2	Inhibitor	/	否
HY-141486A	PROTAC PARP/EGFR ligand 1		/	否
HY-146474	EGFR-IN-54	Inhibitor	/	否
HY-157432	EGFR-IN-97	Inhibitor	/	否
HY-147796	EGFR/HER2/CDK9-IN-1	Inhibitor	/	否
HY-110333	BMS-599626 dihydrochloride	Inhibitor	/	否
HY-151882	EGFR-IN-73	Inhibitor	/	否
HY-146471	EGFR-IN-51	Inhibitor	/	否
HY-158178	EGFR T790M/L858R-IN-7	Inhibitor	/	否
HY-144605	PROTAC EGFR degrader 3	Inhibitor	97.39%	否
HY-B0794S	AZ7550-d5	Inhibitor	/	否
HY-144760	EGFR-IN-3	Inducer	/	否
HY-169427	FRF-06-057	Inhibitor	/	否
HY-169428	EGFR-IN-138		/	否
HY-143733	HER2-IN-5	Inhibitor	/	否
HY-157324	EGFR-IN-94	Inhibitor	/	否
HY-131710	PDE5-IN-3	Inhibitor	/	否
HY-142681	EGFR-IN-28	Inhibitor	/	否
HY-161923	EGFR-IN-120	Inhibitor	/	否
HY-P10659	Self-assembling peptide pY1		/	否
HY-156114	EGFR/CDK2-IN-2	Inhibitor	/	否
HY-168151	EGFR-IN-128	Inhibitor	/	否
HY-161136	EGFR/STAT3-IN-1	Inhibitor	/	否
HY-153744	JGK-068S	Inhibitor	/	否
HY-P5258	Oligopeptide-41	Inducer	/	否
HY-142283BS	N-Desmethyl dosimertinib-d5		/	否
HY-139884	EGFR-IN-18	Inhibitor	/	否
HY-158016	Antiproliferative agent-49	Inhibitor	/	否
HY-162300	EGFR kinase inhibitor 4	Inhibitor	/	否
HY-147967	EGFR-IN-63	Inhibitor	/	否
HY-168112	EGFR-IN-127	Inhibitor	/	否
HY-163663	AZ14133346	Inhibitor	/	否
HY-147826	EGFR-IN-60	Inhibitor	/	否
HY-50898S3	Lapatinib-d4-1	Inhibitor	/	否
HY-W174279	Tyrphostin 8	Inhibitor	≥98.0%	否
HY-114535	Jaceidin	Inhibitor	/	否
HY-149518	EGFR/BRAFV600E-IN-3	Inhibitor	/	否
HY-144676	pan-HER-IN-1	Inhibitor	/	否
HY-142680	EGFR-IN-23	Inhibitor	/	否
HY-164392	TAS-121	Inhibitor	/	否
HY-163860	EGFR-TK-IN-3	Inhibitor	/	否
HY-108931	AG 1406	Inhibitor	99.03%	否
HY-147996	EGFR-IN-67	Inhibitor	/	否
HY-164056	EGFR T790M/L858R-IN-8	Inhibitor	99.20%	否
HY-149695	EGFR-IN-91	Inhibitor	/	否
HY-163880	EGFR-IN-119	Inhibitor	/	否
HY-162881	DS06652923	Inhibitor	/	否
HY-144054	EGFR-IN-37	Inhibitor	/	否
HY-144052	EGFR-IN-35	Inhibitor	/	否
HY-157526	EGFR-TK-IN-1	Inhibitor	/	否
HY-RS04210	Egfr Mouse Pre-designed siRNA Set A	Inhibitor	/	否
HY-142678	EGFR-IN-21	Inhibitor	/	否
HY-B0793S1	AZ-5104-d2	Inhibitor	/	否
HY-147994	EGFR/HER2-IN-5	Inhibitor	/	否
HY-101959	Tyrphostin AG213	Inhibitor	/	否
HY-162623	EGFR/HER2-IN-15	Inhibitor	/	否
HY-110039	BIBX 1382 dihydrochloride	Inhibitor	/	否
HY-100064S	O-Desmethyl gefitinib-d8	Inhibitor	99.84%	否
HY-161030	EGFR-IN-92	Inhibitor	/	否
HY-156991	NODAGA-NHS		/	否
HY-160564	ZNL-0056	Inhibitor	/	否
HY-156457	EGFR-IN-90	Inhibitor	/	否
HY-151161	EGFR/HER2-IN-8	Inhibitor	/	否
HY-161031	EGFR-IN-93	Inhibitor	/	否
HY-15772S3	Asandeutertinib	Inhibitor	/	否
HY-158177	EGFR T790M/L858R-IN-6	Inhibitor	/	否
HY-151156	EGFR/HER2-IN-6	Inhibitor	/	否
HY-146782	EGFR-IN-49	Inhibitor	/	否
HY-164490	LS-106	Inhibitor	/	否
HY-146423	PROTAC EGFR degrader 6	Inhibitor	/	否
HY-164702	BL-B01D1	Inhibitor	/	否
HY-101960	(Z)-Tyrphostin A51	Inhibitor	/	否
HY-13314A	Tesevatinib tosylate	Inhibitor	/	否
HY-161269	EGFR-IN-101	Inhibitor	/	否
HY-151981	EGFR-IN-74	Inhibitor	/	否
HY-162062	EGFR WT/T790M/L858R-IN-1	Inhibitor	/	否
HY-163371	EGFR WT/T790M-IN-1	Inhibitor	/	否
HY-163417	HER2-IN-15	Inhibitor	/	否
HY-13595R	Chrysophanol (Standard)	Inhibitor	/	否
HY-161618	MJ04	Inhibitor	/	否
HY-147992	EGFR/HER2-IN-4	Inhibitor	/	否
HY-155969	EGFR-IN-83	Inhibitor	/	否
HY-168559	EGFR-IN-131	Inhibitor	/	否
HY-155200	EGFR-IN-84	Inhibitor	/	否
HY-142283CS	N-Methyl-dosimertinib-d5		/	否
HY-157398	EGFR T790M/L858R-IN-3	Inhibitor	/	否
HY-168064	EGFR-IN-124	Inhibitor	/	否
HY-137786	EGFR-IN-16	Inhibitor	/	否
HY-161319	EGFR-IN-104	Inhibitor	/	否
HY-144055	EGFR-IN-38	Inhibitor	/	否
HY-144056	EGFR-IN-39	Inhibitor	/	否
HY-13524A	AG-1478 hydrochloride	Inhibitor	/	否
HY-W423595	BEBT-109	Inhibitor	/	否
HY-10261E	(R)-Afatinib	Inhibitor	/	否
HY-123035	Gamendazole	Inhibitor	/	否
HY-N3634	Corylifol C		/	否
HY-147798	EGFR/HER2/CDK9-IN-3	Inhibitor	/	否
HY-156116	EGFR/CDK2-IN-4	Inhibitor	/	否
HY-159519	EGFR/HER2-IN-16	Inhibitor	/	否
HY-158176	EGFR T790M/L858R-IN-5	Inhibitor	/	否
HY-149846	SIQ17	Inhibitor	/	否
HY-156741	EGFR-IN-87	Inhibitor	/	否
HY-139997	DDC-01-163	Degrader	/	否
HY-143901	EGFR-IN-40	Inhibitor	/	否
HY-146210	EGFR-IN-50	Inhibitor	/	否
HY-150782	UNC-CA359	Inhibitor	/	否
HY-159512	EGFR kinase inhibitor 7	Inhibitor	/	否
HY-147802	EGFR-IN-59	Inhibitor	/	否
HY-161320	EGFR-IN-105	Inhibitor	/	否
HY-146136	EGFR-IN-56	Inhibitor	/	否
HY-144097	HER2-IN-8	Inhibitor	/	否
HY-162148	HNPMI	Inhibitor	99.57%	否
HY-144444	NSC381467	Inhibitor	/	否
HY-151159	DHFR-IN-4	Inhibitor	99.19%	否
HY-164399	SST0116CL1	Degrader	/	否
HY-169308	EGFR-IN-132	Inhibitor	/	否
HY-19985A	(3S,4S)-PF-06459988		99.85%	否
HY-163418	HER2-IN-17	Inhibitor	/	否
HY-146422	PROTAC EGFR degrader 5	Inhibitor	/	否
HY-149407	Multi-kinase-IN-4	Inhibitor	/	否
HY-161146	EGFR-IN-100	Inhibitor	/	否
HY-153557	HER2-IN-13	Inhibitor	/	否
HY-127067	Yuanhuadin	Inhibitor	/	否
HY-162099	VEGFR-IN-4	Inhibitor	/	否
HY-144049	EGFR-IN-32	Inhibitor	/	否
HY-147997	EGFR-IN-68	Inhibitor	/	否
HY-151048	JBJ-07-149	Inhibitor	/	否
HY-142519	EGFR-IN-27	Inhibitor	/	否
HY-162332	EGFR-PK/JNK-2-IN-1	Inhibitor	/	否
HY-100636	Gefitinib N-oxide	Inhibitor	/	否
HY-147995	EGFR-IN-64	Inhibitor	/	否
HY-164387A	Sutetinib maleate	Inhibitor	/	否
HY-145867	EGFR-IN-45	Inhibitor	/	否
HY-145824	EGFR-IN-43	Inhibitor	/	否
HY-163453	HER2-IN-19	Inhibitor	/	否
HY-162964	EGFR-IN-126	Inhibitor	/	否
HY-P10569	Biotin HER-2 substrate peptide		/	否
HY-151158	EGFR/HER2-IN-7	Inhibitor	/	否
HY-142517	EGFR-IN-25	Inhibitor	/	否
HY-402309	IGF-1R modulator 1	Modulator	/	否
HY-160613	EGFR/HER2-IN-11	Inhibitor	/	否
HY-164413	CLM3	Inhibitor	/	否
HY-146228	HSP90-IN-13	Inhibitor	/	否
HY-144445	NSC114126	Inhibitor	/	否
HY-162323	EGFR-IN-106	Inhibitor	/	否
HY-162891	EGFR-IN-123	Inhibitor	/	否
HY-153856A	TAS2940 fumarate	Inhibitor	/	否
HY-161785	EGFR-IN-117	Inhibitor	/	否
HY-161891	EGFR/Akt-IN-1	Inhibitor	/	否
HY-151377	RET-IN-19	Inhibitor	/	否
HY-159101	EP26	Inhibitor	/	否
HY-10368	EGFR/VEGFR2-IN-4	Inhibitor	/	否
HY-143874	HER2-IN-7	Inhibitor	/	否
HY-162360	EGFR-IN-109	Inhibitor	/	否
HY-163419	HER2-IN-18	Inhibitor	/	否
HY-100663	Gefitinib impurity 2		99.56%	否
HY-164988	TX2-120-1	Degrader	/	否
HY-161968	EGFR/PI3Kα-IN-1	Inhibitor	/	否
HY-18213	EGFR-IN-9	Inhibitor	98.84%	否
HY-146238	EGFR/HER2/TS-IN-1	Inhibitor	/	否
HY-115933	EGFR/BRAF-IN-1	Inhibitor	/	否
HY-144044	EGFR-IN-30	Inhibitor	/	否
HY-156470	Multi-kinase-IN-6	Inhibitor	/	否
HY-169309	EGFR-IN-133	Inhibitor	/	否
HY-160068	2-2(t) aptamer sodium	Chemical	/	否
HY-147825	EGFR/BRAFV600E-IN-1	Inhibitor	/	否
HY-164718	Sevabertinib	Inhibitor	/	否
HY-168627	EGFR-IN-135	Inhibitor	/	否
HY-157166	EGFR kinase inhibitor 2	Inhibitor	/	否
HY-144441	NSC81111	Inhibitor	/	否
HY-169346	Pred17	Inhibitor	/	否
HY-153856	TAS2940	Inhibitor	/	否
HY-145844	EGFR-IN-44	Inhibitor	/	否
HY-158175	EGFR T790M/L858R-IN-4	Inhibitor	/	否
HY-144794	EGFR-IN-46	Inhibitor	/	否
HY-101958	Tyrphostin 25	Inhibitor	99.00%	否
HY-P2548	pp60 (v-SRC) Autophosphorylation Site, Phosphorylated		/	否
HY-161602	EGFR/HER2-IN-13	Inhibitor	/	否
HY-147860	EGFR-IN-61	Inhibitor	/	否
HY-146170	Anticancer agent 69	Inhibitor	/	否
HY-146473	EGFR-IN-53	Inhibitor	/	否
HY-155074	EGFR-IN-79	Inhibitor	/	否
HY-168623	EGFR-IN-134	Inhibitor	/	否
HY-163000	EGFR-IN-129	Inhibitor	/	否
HY-146472	EGFR-IN-52	Inhibitor	/	否
HY-149632	EGFR/HER2/DHFR-IN-2	Inhibitor	/	否
HY-149275	PKM2/PDK1-IN-1	Inhibitor	/	否
HY-12008S1	Erlotinib-13C6 hydrochloride		/	否
HY-160682	EGFR/HER2-IN-12	Inhibitor	/	否
HY-155118	EGFR-IN-81	Inhibitor	/	否
HY-P1085	Epidermal Growth Factor Receptor Peptide (985-996)	Chemical	/	否
HY-143445	EGFR-IN-48	Inhibitor	/	否
HY-110328	PKI-166 hydrochloride	Inhibitor	/	否
HY-161632	PROTAC EGFR degrader 10	Degrader	/	否
HY-161145	EGFR/microtubule-IN-1	Inhibitor	/	否
HY-112474	Tyrphostin AG 112	Inhibitor	98.55%	否
HY-129510	4-Methyl erlotinib	Inhibitor	/	否
HY-164387	Sutetinib	Inhibitor	/	否
HY-163420	HER2-IN-16	Inhibitor	/	否
HY-P4082	ErbB-2-binding peptide		99.83%	否
HY-121828	TX-1123	Inhibitor	/	否
HY-151154	EGFR/HER2/DHFR-IN-1	Inhibitor	/	否
HY-50896S1	Erlotinib-13C6	Inhibitor	/	否
HY-162788	EGFR-IN-121	Inhibitor	/	否
HY-161603	EGFR/HER2-IN-14	Inhibitor	/	否
HY-146132	EGFR-IN-55	Inhibitor	/	否
HY-149401	EGFR-IN-82	Inhibitor	/	否
HY-162602	EGFR-IN-115	Inhibitor	/	否
HY-50898S2	Lapatinib-d5	Inhibitor	/	否
HY-155178	Antiproliferative agent-34	Inhibitor	/	否
HY-152019	EGFR/C797S-IN-1	Inhibitor	/	否
HY-164992	Trastuzumab MMAE	Inhibitor	/	否
HY-161045	T-1-DOCA	Inhibitor	/	否
HY-150905	EGFR ligand-2	Inhibitor	/	否
HY-149633	EGFR/HER2/DHFR-IN-3	Inhibitor	/	否
HY-10261S1	Afatinib-d4	Inhibitor	/	否
HY-163377	AZ5385	Inhibitor	/	否
HY-18298	PD 173955 analog 1	Inhibitor	/	否
HY-151162	HER2-IN-12	Inhibitor	/	否
HY-156115	EGFR/CDK2-IN-3	Inhibitor	/	否
HY-161866	EGFR-IN-118	Inhibitor	/	否
HY-156639	EGFR/ErbB-2 inhibitor-1	Inhibitor	/	否
HY-13050A	Sapitinib fumarate	Inhibitor	/	否
HY-146138	EGFR-IN-57	Inhibitor	/	否
HY-135216	Antiproliferative agent-54	Inhibitor	/	否
HY-115952	EGFR/HER2-IN-3	Inhibitor	/	否
HY-15268	PP487	Inhibitor	/	否
HY-146154	EGFR-IN-58	Inhibitor	/	否
HY-161067	EGFR-IN-96	Inhibitor	/	否
HY-163006	EGFR/c-Met-IN-1	Inhibitor	/	否
HY-149344	Anticancer agent 133	Inhibitor	/	否
HY-19730A	Olmutinib hydrochloride	Inhibitor	/	否
HY-W008914	(E/Z)-CP-724714	Inhibitor	/	否
HY-50898S1	Lapatinib-d7 dihydrochloride	Inhibitor	/	否
HY-168173	EGFR-IN-130	Inhibitor	/	否
HY-147862	EGFR-IN-62	Inhibitor	/	否
HY-144053	EGFR-IN-36	Inhibitor	/	否
HY-156033	EGFR-IN-88	Inhibitor	/	否
HY-163722	EGFR/DHFR-IN-1	Inhibitor	/	否
HY-157912	EGFR-IN-102	Inhibitor	/	否
HY-162890	EGFR-IN-122	Inhibitor	/	否
HY-144051	EGFR-IN-34	Inhibitor	/	否
HY-142679	EGFR-IN-22	Inhibitor	/	否
HY-151573	EGFR/CDK2-IN-1	Inhibitor	/	否
HY-147797	EGFR/HER2/CDK9-IN-2	Inhibitor	/	否
HY-135725	D-69491 hydrochloride	Inhibitor	/	否
HY-15769A	WHI-P180 hydrochloride	Inhibitor	/	否
HY-50895S2	Gefitinib-d3	Inhibitor	/	否
HY-W740378	1,2,3,4-Tetrahydro Staurosporin	Inhibitor	/	否
HY-157582	MS39N	Inhibitor	/	否
HY-163396	EGFR-IN-107	Inhibitor	/	否
HY-164464	BPI-15086	Inhibitor	/	否
HY-164763	SHR-A1201	Inhibitor	/	否
HY-21291	SU-4313	Modulator	/	否
HY-123766	EGFR-IN-99	Inhibitor	/	否
HY-16069S	Tucatinib-d6	Inhibitor	/	否
HY-114667	Lavendustin C6	Inhibitor	/	否
HY-164503	Neptinib	Inhibitor	/	否
HY-19909A	NRC-2694-A	Inhibitor	/	否
HY-103443A	HKI-357 dimaleate	Inhibitor	/	否
HY-P10648	Herceptide		/	否
HY-137433A	Befotertinib mesylate	Inhibitor	/	否
HY-50898CS	Lapatinib-d4 tosylate	Inhibitor	/	否
HY-117523	(Z)-RG-13022	Inhibitor	/	否
HY-164527	Si306	Inhibitor	/	否
HY-164762	Trastuzumab rezetecan	Inhibitor	/	否
HY-110045	ZM-306416 hydrochloride	Inhibitor	/	否
HY-129288	GW837016X	Inhibitor	/	否
HY-164919	Calotatug ginistinag	Inhibitor	/	否
HY-164476	ES-072	Inhibitor	/	否
HY-135727	PF-6422899	Inhibitor	/	否
HY-168305	EGFR ligand-11		/	否
HY-32721S	Neratinib-d6	Inhibitor	/	否
HY-146262	LDC0496	Inhibitor	/	否
HY-100520	EGFR-IN-2	Inhibitor	/	否
HY-110406	13(S)-HPODE	Activator	/	否

抗体抑制剂 (21)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-P9912A	Pertuzumab (anti-HER2)	Inhibitor	99.10%	否
HY-P99684	Laprituximab	Inhibitor	≥95.0%	否
HY-P99892	Serclutamab		99.97%	否
HY-P990972	Azerutamig		/	否
HY-P990957	Ficerafusp alfa		/	否
HY-P990913	Dalmitamig		/	否
HY-P990947	Tilatamig		/	否
HY-P990962	Vislarafusp alfa		/	否
HY-P99888	Pimurutamab		/	否
HY-P99324	Tomuzotuximab	Inhibitor	/	否
HY-P990909	Calotatug		/	否
HY-P990978	Caxmotabart		/	否
HY-P99948	Etevritamab		/	否
HY-P990698	Umizortamig		/	否
HY-P990055	Nezutatug	Inhibitor	/	否
HY-P990695	Lunaxafusp	Inhibitor	/	否
HY-P99406A	Petosemtamab (FUT8-KO)		/	否
HY-P99558	Timigutuzumab	Inhibitor	/	否
HY-P990755	Pamvatamig		/	否
HY-P990697	Anvatabart	Inhibitor	/	否
HY-P9977A	Amivantamab (FUT8-KO)	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Egfr	NCBI	NCBI:1956
Canis familiaris	Egfr	NCBI	NCBI:404306
Macaca fascicularis	Egfr	NCBI	NCBI:102138724
Rattus norvegicus	Egfr	NCBI	NCBI:24329
Macaca mulatta	Egfr	NCBI	NCBI:613027

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.